Skip to main content
. 2014 Nov 24;9(11):e113587. doi: 10.1371/journal.pone.0113587

Figure 6. A 56-year-old male glioblastoma patient with a measurable enhancing lesion after adjuvant TMZ.

Figure 6

The 99th percentile nCBV value and PFS of this patient were 5.5 and 8.9 months, respectively. (A) An axial contrast-enhanced T1WI obtained within 3 months after CCRT and adjuvant TMZ shows a measurable enhancing lesion in the left frontal cortex. (B) The nCBV map and ROIs (red color) are displayed as a color overlay on the contrast-enhanced T1WI. (C) ADC map with ROIs (red color) are displayed as a color overlay (in hot scale) on the contrast-enhanced T1WI. (D) The volume rendering contrast-enhancement T1WI from measurable enhancing lesion shows the volume (red color) of measurable enhancing lesion at the time of progression. (E, F) The nCBV and ADC histograms of measurable enhancing lesion.